STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Overview of Jaguar Health Inc

Jaguar Health Inc (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops innovative, plant-based prescription medicines sustainably derived from rainforest botanical sources. Operating within the natural pharmaceuticals and gastrointestinal therapeutics sectors, the company focuses on non-opioid, anti-secretory agents to address chronic gastrointestinal distress in both human and animal populations. With an emphasis on sustainable practices and fair trade, Jaguar Health harnesses traditional botanical knowledge to deliver solutions for chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.

Core Business and Product Portfolio

At its core, Jaguar Health is committed to developing novel treatments for overactive bowel conditions. The company is recognized for its pioneering work with crofelemer, a naturally derived anti-secretory agent that exhibits a normalizing effect on the gastrointestinal tract. Mytesi®, for example, is an approved prescription drug providing symptomatic relief for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In addition, Jaguar Health leverages its research through its fully-owned subsidiary, Napo Pharmaceuticals, which is dedicated to broadening the therapeutic reach of these treatments across human health scenarios, including cancers and other complex GI conditions.

Beyond human pharmaceuticals, Jaguar Health applies its expertise to the animal health segment with targeted products. Canalevia™ is a prescription drug candidate aimed at treating various forms of diarrhea in dogs, while Equilevia™ focuses on total gut health in equine athletes. These offerings position the company uniquely by addressing both human and veterinary needs with a unified approach to gastrointestinal wellness.

Scientific and Sustainable Approach

Jaguar Health stands out for its deep commitment to sustainability and scientific innovation. The active compounds are harvested from plants traditionally used in rainforest regions, ensuring ecological integrity and supporting indigenous communities. The company’s research into crofelemer underscores its potential to benefit multiple gastrointestinal disorders through its unique, local anti-secretory mechanism. This scientifically rigorous approach is supported by numerous clinical efforts and trials, demonstrating a profound understanding of complex biological pathways and unmet medical needs.

Market Position and Industry Relevance

Positioned within the competitive natural pharmaceuticals and gastrointestinal markets, Jaguar Health distinguishes itself through its sustainable sourcing, proprietary botanical research, and commitment to addressing neglected gastrointestinal symptoms. Its products are developed to offer significant improvements in patient quality of life and demonstrate a safety profile that supports chronic utilization. The company's diversified segments in both human and animal health provide resilience and stability within a niche market, making it a noteworthy entity for investors and industry analysts seeking depth in biotechnology innovation.

Operational Excellence and Global Reach

Jaguar Health operates across multiple markets with a focus on sustainable, clinically validated therapeutic solutions. Its integrated business model, combining research and commercial expertise via subsidiaries like Napo Pharmaceuticals, allows it to conduct extensive clinical investigations, including proof-of-concept and Phase 2 studies. By embedding traditional botanical wisdom within a modern regulatory framework, Jaguar Health ensures that its therapeutic offerings remain both innovative and aligned with global healthcare standards.

Expertise, Experience, and Trustworthiness

The company’s operations are underpinned by a team of experienced scientists and clinicians who are experts in gastrointestinal research, natural product formulation, and clinical trial management. This multi-disciplinary approach reinforces Jaguar Health's commitment to providing balanced, evidence-based information while upholding the highest levels of expertise and authoritativeness. The emphasis on sustainability and thorough clinical validation further positions Jaguar Health as a trusted source in the pharmaceutical industry.

Conclusion

In summary, Jaguar Health Inc is a pioneering force in the development of natural, plant-based prescription medicines for gastrointestinal distress, serving both human and animal health sectors. Its sustainable sourcing, commitment to scientific rigor, and innovative product portfolio make it a significant player in the natural pharmaceutical landscape. Through strategic research and development, Jaguar Health continues to address unmet medical needs and advance treatment options for chronic gastrointestinal disorders.

Rhea-AI Summary

Jaguar Health announced that its product Canalevia-CA1, a canine formulation of crofelemer, has received conditional approval from the FDA for treating chemotherapy-induced diarrhea (CID) in dogs. This marks a significant advancement in mitigating the severe side effects of chemotherapy in canines. The FDA's recognition highlights the importance of extending quality of life during cancer treatments. Canalevia-CA1 is the first oral plant-based prescription specifically approved for this purpose and aims to support dog owners and veterinarians.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has received conditional approval from the FDA for Canalevia-CA1, the first oral plant-based treatment for chemotherapy-induced diarrhea (CID) in dogs. This product, derived from the Croton lechleri tree, addresses a significant need as CID affects many dogs undergoing cancer treatment. Approximately 1 in 4 dogs may develop cancer, with many experiencing CID as a side effect. Jaguar plans to reveal more commercialization details in January 2022, filling a critical gap in canine cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
Rhea-AI Summary

Jaguar Health (JAGX) announced that the European Commission has granted Orphan Drug Designation to crofelemer for treating short bowel syndrome (SBS). This milestone follows the application submitted by Napo EU, Jaguar's Italian subsidiary. SBS affects 10,000 to 20,000 individuals in the U.S. and Europe. The global SBS market was valued at over $568 million in 2019 and is projected to reach $4.6 billion by 2027. Napo EU plans to initiate a pivotal clinical trial aiming for accelerated marketing authorization in Europe for crofelemer, which has received similar designation in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Summary

Jaguar Health has presented findings from the HALT-D trial, evaluating the efficacy of crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients. The study involved 51 patients treated with crofelemer or standard care. While the primary endpoint showed no statistical difference in diarrhea incidence, significant improvements were noted in several secondary endpoints, including lower CID occurrence in the crofelemer group (23%). These results provide proof-of-concept data and underscore the need for effective prophylactic treatments for CID during chemotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) is set to host a closed satellite event on December 9, 2021, at the San Antonio Breast Cancer Symposium (SABCS) to discuss cancer therapy-related diarrhea. The event will feature oncologists and a presentation on the ongoing OnTarget Pivotal Phase 3 trial of crofelemer, aimed at preventing diarrhea in adult cancer patients receiving targeted therapies. Data from the HALT-D trial will also be presented, evaluating crofelemer for chemotherapy-induced diarrhea in HER2-positive breast cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences clinical trial
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced topline results from the Phase 2 HALT-D trial for crofelemer in preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients. The trial, involving 51 patients, saw an overall incidence of diarrhea around 70%, showing no significant difference between crofelemer and control groups. However, secondary endpoints indicated crofelemer led to a lower incidence of grade 2 or higher diarrhea compared to standard care. These results support further testing and endpoint selection for the ongoing Phase 3 OnTarget trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
-
Rhea-AI Summary

Jaguar Health reported a 7.6% increase in Mytesi prescription volume in Q3 2021, with net sales around $0.6 million. Despite a decrease in gross revenue to $3.2 million, the company is transitioning to a closed specialty pharmacy network to improve patient access. Upcoming milestones include the presentation of Phase 2 HALT-D study results and the launch of Canalevia-CA1 for dogs. The company reported a net loss of $12.2 million for Q3 2021, a significant increase from $7.9 million in Q3 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.9%
Tags
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) has appointed Massimo Mineo as General Manager of its Italian subsidiary, Napo EU. With over 20 years of pharmaceutical experience, Mineo will spearhead strategies for the marketing authorization of crofelemer, targeting short bowel syndrome with intestinal failure, a rare disease. His prior roles included leading commercial operations at Recordati Rare Diseases, where he successfully launched orphan drugs. The appointment is expected to strengthen Napo EU's market presence in Europe, enhancing access to crofelemer for patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
management
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced a rescheduled investor webcast for reviewing Q3 2021 financials on November 17, 2021, at 8:30 AM ET. The change is due to additional time required for finalizing accounting aspects of the recent merger with Dragon SPAC S.p.A. and Napo EU S.p.A.

Jaguar focuses on developing plant-based medicines for GI distress, particularly targeting chronic diarrhea. Its product Mytesi is FDA-approved for relieving noninfectious diarrhea in HIV/AIDS patients on antiretroviral therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $4.76 as of April 1, 2025.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 3.1M.

What is Jaguar Health Inc's core business?

Jaguar Health Inc focuses on developing novel, plant-based prescription medicines for gastrointestinal distress in both humans and animals. The company leverages sustainable botanical sources to create non-opioid, anti-secretory therapies.

How does Jaguar Health generate its revenue?

The company generates revenue primarily through its human health segment, which includes the commercialization of therapies like Mytesi® for symptomatic relief of noninfectious diarrhea. Additionally, its animal health segment provides targeted treatments for companion and performance animals.

What makes Jaguar Health's products unique?

Jaguar Health develops therapies using sustainably harvested, rainforest-derived botanicals, ensuring ecological integrity and traditional medicinal value. Their products, such as crofelemer-based therapies, offer localized therapeutic effects that address multiple gastrointestinal disorders.

What are some of the company's key products?

Key products include Mytesi®, a prescription drug for relieving chronic noninfectious diarrhea in adults with HIV/AIDS, and other candidates like Canalevia™ for canine diarrhea and Equilevia™ for equine gut health. These products exemplify their dual focus on human and animal health.

How does Jaguar Health incorporate sustainability into its operations?

Jaguar Health sources its active botanical ingredients from rainforest plants using sustainable harvesting practices and fair trade principles. This approach not only ensures high-quality, natural compounds but also supports indigenous communities and preserves ecological integrity.

Who are the target customers of Jaguar Health?

The company's target customers include patients suffering from chronic gastrointestinal disorders, both in human medicine and veterinary care. It also serves healthcare providers and veterinary professionals seeking natural and sustainable therapeutic solutions.

How does Jaguar Health differentiate itself from competitors?

Jaguar Health distinguishes itself through its commitment to sustainable, plant-based research, a diversified product portfolio across human and animal health, and a rigorous clinical approach backed by extensive scientific expertise. Its unique botanical sourcing and innovative formulations set it apart in the natural pharmaceuticals market.

What role does Napo Pharmaceuticals play in Jaguar Health's business?

Napo Pharmaceuticals, a wholly-owned subsidiary of Jaguar Health, is dedicated to developing and commercializing human prescription pharmaceuticals. It plays a crucial role in extending the company’s reach in addressing neglected gastrointestinal symptoms through advanced clinical research and product development.
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

3.14M
558.90k
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO